Renee Williams, MD, MHPE

Key Takeaways in Colorectal Cancer Screening

In the final episode, ‘Key Takeaways in Colorectal Cancer Screening,’ the faculty emphasize that while colonoscopy remains the gold standard, noninvasive stool-based tests are appropriate alternatives for average-risk patients who decline invasive screening. They stress that symptomatic or high-risk individuals—including those with family history, genetic syndromes, inflammatory bowel disease, or prior polyps—require diagnostic colonoscopy rather than screening tests. The discussion highlights emerging DNA- and RNA-based technologies as promising tools to expand screening uptake, particularly given workforce limitations in gastroenterology. With the screening age lowered to 45, capacity constraints have prompted ongoing conversations about how best to allocate colonoscopy resources. Ultimately, the segment reinforces the importance of individualized risk assessment, patient education, and shared decision-making to reduce colorectal cancer morbidity and mortality. Thank you for watching this HCP Live Peers &

Videos

Explore evolving colorectal cancer screening, from colonoscopy to advanced DNA/RNA stool tests, plus risk-based strategies and shared decisions that boost early detection.

Coordinating Care After Abnormal Colorectal Cancer Results

In ‘Coordinating Care After Abnormal Colorectal Cancer Screening Results,’ the expert faculty focus on the critical importance of timely follow-up after a positive colorectal cancer screening test. The speakers discuss real-world challenges in referring patients to gastroenterology, including specialist availability and scheduling delays, while emphasizing that diagnostic colonoscopy should ideally occur within six months. They highlight the responsibility of primary care clinicians to “close the loop” and ensure completion of colonoscopy, using tools such as telehealth and proactive follow-up. The conversation also clarifies appropriate next steps after positive tests, including when upper endoscopy is or is not indicated and how to interpret high-quality prior colonoscopy results. Finally, the faculty stress that symptomatic patients and those with iron deficiency anemia require diagnostic evaluation rather than screening tests, reinforcing a risk-based and patient-centered approach to care.

Our next episode, ‘Key Takeaways in Colorectal Cancer Screening,’ the expert faculty reinforce that colorectal cancer screening should be individualized based on risk, symptoms, and patient preference, with colonoscopy reserved for high-risk or symptomatic patients and noninvasive options appropriate for average-risk individuals. The discussion emphasizes shared decision-making, appropriate use of emerging technologies, and the importance of increasing screening rates to reduce both mortality and morbidity from colorectal cancer.

Positive FIT/Cologuard? See why follow-up colonoscopy is often $0 and how navigation, rides, and time-off support boost screening.

Addressing Access Barriers in Colorectal Cancer Screening

In this episode, ‘Addressing Access Barriers in Colorectal Cancer Screening,’ the panelists explore common patient concerns about the cost of colonoscopy following a positive colorectal cancer screening test. The speakers clarify that stool-based screening tests and subsequent diagnostic colonoscopy are generally covered by insurance, including procedures involving polyp removal and surveillance. They emphasize that financial worries, along with time off work and logistical challenges, can significantly reduce adherence. The discussion also highlights the growing role of health systems in addressing social drivers of health, such as transportation assistance and patient navigation services. Ultimately, the faculty underscore the importance of proactively addressing cost and access concerns to improve screening completion rates and reduce colorectal cancer disparities.

The next episode in this series, ‘Coordinating Care After Abnormal Colorectal Cancer Results,’ focuses on the importance of timely follow-up after a positive stool test, ideally within six months, closing the referral loop to gastroenterology, avoiding inappropriate stool testing in symptomatic patients, and ensuring that noticeable symptoms prompt direct diagnostic evaluation rather than screening.

Positive stool test? Learn why follow-up colonoscopy is often covered and how clinics tackle cost, time-off, and transport barriers.

 Individualizing When to Stop Colorectal Cancer Screening 

This episode, titled ‘Individualizing When to Stop Colorectal Cancer Screening,’ examines the nuanced decision-making involved in determining when to discontinue colorectal cancer screening. While guidelines generally recommend screening from ages 45 to 75, faculty emphasize the importance of individualizing decisions based on overall health, life expectancy, and patient preferences. The discussion highlights that screening may remain appropriate for robust older adults, while it may not benefit patients with limited life expectancy due to advanced comorbid conditions. Speakers underscore the importance of framing conversations around overall health priorities rather than age alone, using shared decision-making to guide recommendations. Ultimately, the segment reinforces that stopping screening is not a rigid cutoff but a thoughtful, patient-centered clinical judgment.

In the next episode, ‘Addressing Access Barriers in Colorectal Cancer Screening,’ panelists will continue their discussion on colorectal cancer screening and address financial concerns related to follow-up colonoscopy after a positive screening test, emphasizing that most costs are covered by insurance and that removing financial misconceptions can improve adherence. The discussion also highlights the broader impact of social determinants of health, such as transportation, time off work, and childcare, and the role of patient navigation in improving screening completion rates.

See how FIT cutoffs change accuracy, why Cologuard raises sensitivity

Renee Williams, MD, MHPE

Articles